Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K16/10

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/207635PRUSSIAN BLUE NANOPARTICLES FUNCTIONALIZATION WITH LATENCY REVERSING AGENTS AND BROADLY NEUTRALIZING ANTIBODIES, AND APPLICATIONS THEREOF
WO 14.10.2021
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
Appl.No PCT/US2021/026632 Applicant THE GEORGE WASHINGTON UNIVERSITY Inventor FERNANDES, Rohan
Embodiments of the instant disclosure relate to novel compositions and methods for the treatment of retroviruses (e.g., HIV) and the reduction and/or eradication of latent HIV reservoirs. Compositions herein may include biofunctionalized nanocomposites comprised of a core nanoparticle formed of Prussian blue materials, a shell obtained by partially or completely encapsulating the Prussian blue core with at least one biocompatible coating, and at least one biomolecule attached to, or absorbed to, the biocompatible coating and uses thereof.
2.WO/2021/207486TREATMENTS
WO 14.10.2021
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2021/026367 Applicant AERIE PHARMACEUTICALS, INC. Inventor DELONG, Mitchell, A.
Described herein are compounds, combinations of compounds, compositions, formulations, and methods of treating viruses, viral load, and manifestations of viral infections.
3.WO/2021/206636ANTIGEN-BINDING PROTEIN TO SARS-CoV-2
WO 14.10.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/SG2021/050195 Applicant AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH Inventor WANG, Cheng-I
The present invention relates to provide antigen-binding proteins that are capable of binding to and/or neutralizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In one embodiment, the antigen-binding proteins are capable of binding to a spike protein of SARS-CoV-2 including receptor-binding domain (RBD) of SARS-CoV-2. The present invention also provides products comprising the same and methods of using the same for the treatment of SARS-CoV-2 infection or for detecting the presence of SARS-CoV-2 in a sample.
4.WO/2021/204969PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST AN INFECTION BY SARS-COV-2 (COVID-19)
WO 14.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/EP2021/059232 Applicant EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET Inventor WALZ, Juliane
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of an infection by SARS-CoV-2 (COVID-19). The present invention furthermore relates to SARS-CoV2-associated T-cell peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-SARS-CoV2 immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
5.WO/2021/205408IGY IMMUNOGLOBULINS TARGETING CORONAVIRUS, METHODS OF PREPARING SAME, AND METHODS OF USING SAME
WO 14.10.2021
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/IB2021/052977 Applicant IGY IMMUNE TECHNOLOGIES AND LIFE SCIENCES INC. Inventor NGUYEN, Huan Huu
The present disclosure provides a method of preparing compositions or vaccines for immunizing or vaccinating egg-laying fowl such as hens against coronavirus. The eggs can be collected and the coronavirus-specific IgY antibodies can be extracted and purified. The coronavirus-specific IgY immunoglobulin composition can be used to treat individuals exposed to, susceptible to, or infected with coronavirus.
6.WO/2021/206638VACCINE AND/OR ANTIBODY FOR VIRAL INFECTION
WO 14.10.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/SG2021/050197 Applicant INTRA-IMMUSG PRIVATE LIMITED Inventor ZENG, Qi
The present invention relates to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) N-protein and/or an immunogenic fragment thereof and uses thereof. The invention also includes a nucleic acid molecule encoding the SARS-CoV-2 N-protein and/or an immunogenic fragment thereof; and uses thereof. The SARS-CoV-2 N protein and/or immunogenic fragment thereof may be produced by recombinant DNA technology or may be chemically synthesised. In particular, the SARS-CoV-2 N-protein and/or an immunogenic fragment thereof and/or nucleic acid molecule encoding the SARS-CoV-2 N-protein and immunogenic may be for use as a vaccine. The invention further includes an antibody capable of binding to the SARS-CoV-2 N-protein or antigen-binding fragment thereof and uses thereof.
7.WO/2021/207433EPITOPES OF SARS-COV-2 NEUTRALIZING ANTIBODIES
WO 14.10.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/026286 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor CHENG, Yifan
The invention provides novel anti-SARS-CoV-2-Spike antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions.
8.20210316009METHODS FOR THE PREPARATION OF A PHARMACEUTICAL-VESICLE FORMULATION AND ASSOCIATED PRODUCTS AND USES
US 14.10.2021
Int.Class A61K 47/69
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
69the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Appl.No 17273059 Applicant THE SECRETARY OF STATE FOR DEFENCE Inventor ETHEL DIANE WILLIAMSON

The invention relates to methods for the preparation of a pharmaceutical-vesicle formulation comprising steps of: preparing and processing vesicle components and a pharmaceutical agent to entrap the pharmaceutical agent in the vesicle and form a pharmaceutical-vesicle formulation, wherein the pharmaceutical-vesicle formulation is reconstituted in a known quantity of the pharmaceutical agent dissolved in a pharmaceutically-acceptable carrier to provide a biphasic pharmaceutical-vesicle formulation. The invention also relates to the associated pharmaceutical-vesicle formulations, pharmaceutical kits and uses as a medicament, in particular for the prevention or treatment of infection by bacteria such as Burkholderia pseudomallei and Francisella tularensis, and viruses such as Venezuelan Equine Encephalitis Virus (VEEV).

9.WO/2021/206581GENETIC CONSTRUCT-BASED VACCINE AGAINST CORONAVIRUS INFECTION
WO 14.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/RU2020/000257 Applicant DUKHOVLINOV, Ilya Vladimirovich Inventor DUKHOVLINOV, Ilya Vladimirovich
The invention relates to molecular biology, biotechnology, medicine and can be used to prevent and treat corona virus infection, mainly caused by 2019-nCoV. A vaccine is proposed based on a genetic construct encoding a fusion protein, including fragments of M, S, N, E new coronavirus proteins. The speed and simplicity of preparation (from 2-3 hours to 4-5 days), safety are the advantages of the developed vaccine, due to the nature of the molecule- of the active substance, as well as to the lack of an ACE2 binding site in the fusion protein synthesized from the genetic construct, and the lack of its homology with proteins of the organism, induction of the immune response profile, to a large extent represented by the cytotoxic immune response, in addition to the humoral one. The vaccine can be administered as standard or by electroporation.
10.3892273COMBINATION PRODUCTS FOR THE TREATMENT OF RSV
EP 13.10.2021
Int.Class A61K 31/437
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
437the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Appl.No 21170919 Applicant JANSSEN SCIENCES IRELAND UNLIMITED CO Inventor YSEBAERT NINA
The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and one or more RSV inhibiting Compound B selected from from ribavirin, GS-5806, MDT-637, BTA-9881, BMS-433771, YM-543403, A-60444, TMC-353121, RFI-641, CL-387626, MBX-300, AZ-27, MEDI8897, CR9501, palivizumab, 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-benzimidazol-2-yl}methyl)-1-cyclopropyl-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, 3-[[7-chloro-3-(2-ethylsulfonylethyl)imidazo[1,2-a]pyridin-2-yl]methyl]-1-cyclopropyl-imidazo[4,5-c]pyridin-2-one, N-(2-fluoro-6-methylphenyl)-6-(4-(5-methyl-2-(7-oxa-2-azaspiro[3.5]nonan-2-yl)nicotinamido)benzoyl)-5,6-dihydro-4H-benzo[b]thieno[2,3-d]azepine-2-carboxamide, and 4-amino-8-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-6,6-dimethyl-2-(4-methyl-3-nitrophenyl)-3H-imidazo[4,5-h]isoquinoline-7,9(6H,8H)-dione , for treating or ameliorating RSV infection. The invention further relates to the combination product of Compound A and one or more Compound B, a pharmaceutical product comprising Compound A and one or more Compound B, the use of the combination of Compound A and one or more of Compound B - or the pharmaceutical product comprising Compound A and one or more Compound B - for the treatment of RSV infection, and a method of treating or ameliorating RSV infection in a subject in need thereof comprising administering the combination of Compound A and one or more Compound B in an effective amount to said subject.